Muscular dystrophy in dysferlin-deficient mouse models

Neuromuscular Disorders

Volumn 23, Issue 5, 2013, Pages 377-387

  Hornsey, Mark A ^a   Laval, Steven H ^a   Barresi, Rita ^b   Lochmüller, Hanns ^a   Bushby, Kate ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE DENTAL HOSPITAL   (United Kingdom)

Author keywords

Dysferlin; Mouse models; Muscular dystrophy

Indexed keywords

CAVEOLIN 3; CD14 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5B; COMPLEMENT MEMBRANE ATTACK COMPLEX; CREATINE KINASE; DECAY ACCELERATING FACTOR; DEFLAZACORT; DYSFERLIN; GLUCOCORTICOID; PYRUVATE KINASE; TRANSCRIPTION FACTOR PAX7; DYSF PROTEIN, MOUSE; MEMBRANE PROTEIN;

CARDIOMYOPATHY; CELL INFILTRATION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG PROTEIN BINDING; DUCHENNE MUSCULAR DYSTROPHY; DYSFERLINOPATHY; HUMAN; MUSCLE ATROPHY; MUSCLE CONTRACTILITY; MUSCLE INJURY; MUSCLE ISOMETRIC CONTRACTION; MUSCLE REGENERATION; MUSCLE STRETCHING; MUTATIONAL ANALYSIS; NEUTROPHIL; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SKELETAL MUSCLE; SPONTANEOUS MUTATION; UPREGULATION; ANIMAL; DEFICIENCY; DISEASE MODEL; GENETICS; METABOLISM; MOUSE; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; MUSCULAR DYSTROPHY; MUTATION; PATHOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MEMBRANE PROTEINS; MICE; MUSCULAR DYSTROPHIES; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; MUTATION;

EID: 84876073994     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2013.02.004     Document Type: Review

References (133)

1. Bashir R., Britton S., Strachan T., et al. A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet 1998, 20:37-42.
2. Laval S.H., Bushby K.M. Limb-girdle muscular dystrophies - from genetics to molecular pathology. Neuropathol Appl Neurobiol 2004, 30:91-105.
3. Guglieri M., Magri F., D'Angelo M.G., et al. Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients. Hum Mutat 2008, 29:258-266.
4. Liu J., Aoki M., Illa I., et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 1998, 20:31-36.
5. Illa I., Serrano-Munuera C., Gallardo E., et al. Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype. Ann Neurol 2001, 49:130-134.
6. Bushby K.M. Making sense of the limb-girdle muscular dystrophies. Brain 1999, 122(Pt 8):1403-1420.
7. Ueyama H., Kumamoto T., Nagao S., et al. A new dysferlin gene mutation in two Japanese families with limb-girdle muscular dystrophy 2B and Miyoshi myopathy. Neuromuscul Disord 2001, 11:139-145.
8. Gayathri N., Alefia R., Nalini A., et al. Dysferlinopathy: spectrum of pathological changes in skeletal muscle tissue. Indian J Pathol Microbiol 2011, 54:350-354.
9. Hicks D., Sarkozy A., Muelas N., et al. A founder mutation in Anoctamin 5 is a major cause of limb-girdle muscular dystrophy. Brain 2011, 134:171-182.
10. Klinge L., Dean A.F., Kress W., et al. Late onset in dysferlinopathy widens the clinical spectrum. Neuromuscul Disord 2008, 18:288-290.
11. Nguyen K., Bassez G., Krahn M., et al. Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. Arch Neurol 2007, 64:1176-1182.
12. Paradas C., Gonzalez-Quereda L., De Luna N., et al. A new phenotype of dysferlinopathy with congenital onset. Neuromuscul Disord 2009, 19:21-25.
13. Klinge L., Harris J., Sewry C., et al. Dysferlin associates with the developing T-tubule system in rodent and human skeletal muscle. Muscle Nerve 2010, 41:166-173.
14. Bittner R.E., Anderson L.V., Burkhardt E., et al. Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B. Nat Genet 1999, 23:141-142.
15. Barresi R. From proteins to genes: immunoanalysis in the diagnosis of muscular dystrophies. Skeletal Muscle 2011, 1.
16. Chiu Y.H., Hornsey M.A., Klinge L., et al. Attenuated muscle regeneration is a key factor in dysferlin-deficient muscular dystrophy. Hum Mol Genet 2009, 18:1976-1989.
17. Gallardo E., Rojas-Garcia R., de Luna N., et al. Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology 2001, 57:2136-2138.
18. Confalonieri P., Oliva L., Andreetta F., et al. Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study. J Neuroimmunol 2003, 142:130-136.
19. Achanzar W.E., Ward S. A nematode gene required for sperm vesicle fusion. J Cell Sci 1997, 110(Pt 9):1073-1081.
20. 2+-triggered exocytosis. Curr Opin Cell Biol 2010, 22:496-505.
21. Therrien C., Dodig D., Karpati G., Sinnreich M. Mutation impact on dysferlin inferred from database analysis and computer-based structural predictions. J Neurol Sci 2006, 250:71-78.
22. Yoshihara M., Montana E.S. The synaptotagmins: calcium sensors for vesicular trafficking. Neuroscientist 2004, 10:566-574.
23. Davis D.B., Doherty K.R., Delmonte A.J., McNally E.M. Calcium-sensitive phospholipid binding properties of normal and mutant ferlin C2 domains. J Biol Chem 2002, 277:22883-22888.
24. Rizo J., Sudhof T.C. Mechanics of membrane fusion. Nat Struct Biol 1998, 5:839-842.
25. Jahn R., Hanson P.I. Membrane fusion. SNAREs line up in new environment. Nature 1998, 393:14-15.
26. 2+-regulated exocytosis of lysosomes. Cell 2001, 106:157-169.
27. Patel P., Harris R., Geddes S.M., et al. Solution structure of the inner DysF domain of myoferlin and implications for limb girdle muscular dystrophy type 2b. J Mol Biol 2008, 379:981-990.
28. Albrecht D.E., Garg N., Rufibach L.E., et al. 4th Annual Dysferlin Conference 11-14 September 2010, Washington, USA. Neuromuscul Disord 2011, 21:304-310.
29. Therrien C., Di Fulvio S., Pickles S., Sinnreich M. Characterization of lipid binding specificities of dysferlin C2 domains reveals novel interactions with phosphoinositides. Biochemistry 2009, 48:2377-2384.
30. Anderson L.V., Davison K., Moss J.A., et al. Dysferlin is a plasma membrane protein and is expressed early in human development. Hum Mol Genet 1999, 8:855-861.
31. Bansal D., Campbell K.P. Dysferlin and the plasma membrane repair in muscular dystrophy. Trends Cell Biol 2004, 14:206-213.
32. Bansal D., Miyake K., Vogel S.S., et al. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 2003, 423:168-172.
33. Glover L., Brown R.H. Dysferlin in membrane trafficking and patch repair. Traffic 2007, 8:785-794.
34. Han R., Campbell K.P. Dysferlin and muscle membrane repair. Curr Opin Cell Biol 2007, 19:409-416.
35. Lennon N.J., Kho A., Bacskai B.J., et al. Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing. J Biol Chem 2003, 278:50466-50473.
36. Cai C., Weisleder N., Ko J.K., et al. Membrane repair defects in muscular dystrophy are linked to altered interaction between MG53, caveolin-3, and dysferlin. J Biol Chem 2009, 284:15894-15902.
37. Demonbreun A.R., Fahrenbach J.P., Deveaux K., et al. Impaired muscle growth and response to insulin-like growth factor 1 in dysferlin-mediated muscular dystrophy. Hum Mol Genet 2011, 20:779-789.
38. Evesson F.J., Peat R.A., Lek A., et al. Reduced plasma membrane expression of dysferlin mutants is attributed to accelerated endocytosis via a syntaxin-4-associated pathway. J Biol Chem 2010, 285:28529-28539.
39. Klinge L., Aboumousa A., Eagle M., et al. New aspects on patients affected by dysferlin deficient muscular dystrophy. J Neurol Neurosurg Psychiatry 2010, 81:946-953.
40. de Morree A., Hensbergen P.J., van Haagen H.H., et al. Proteomic analysis of the dysferlin protein complex unveils its importance for sarcolemmal maintenance and integrity. PLoS One 2010, 5:e13854.
41. Covian-Nares J.F., Koushik S.V., Puhl H.L., Vogel S.S. Membrane wounding triggers ATP release and dysferlin-mediated intercellular calcium signaling. J Cell Sci 2010, 123:1884-1893.
42. Nagaraju K., Rawat R., Veszelovszky E., et al. Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B. Am J Pathol 2008, 172:774-785.
43. Han R., Frett E.M., Levy J.R., et al. Genetic ablation of complement C3 attenuates muscle pathology in dysferlin-deficient mice. J Clin Invest 2010, 120:4366-4374.
44. Wenzel K., Carl M., Perrot A., et al. Novel sequence variants in dysferlin-deficient muscular dystrophy leading to mRNA decay and possible C2-domain misfolding. Hum Mutat 2006, 27:599-600.
45. Wenzel K., Zabojszcza J., Carl M., et al. Increased susceptibility to complement attack due to down-regulation of decay-accelerating factor/CD55 in dysferlin-deficient muscular dystrophy. J Immunol 2005, 175:6219-6225.
46. Lang C.T., Markham K.B., Behrendt N.J., et al. Placental dysferlin expression is reduced in severe preeclampsia. Placenta 2009, 30:711-718.
47. Robinson J.M., Ackerman W.Et., Behrendt N.J., Vandre D.D. While dysferlin and myoferlin are coexpressed in the human placenta, only dysferlin expression is responsive to trophoblast fusion in model systems. Biol Reprod 2009, 81:33-39.
48. Vandre D.D., Ackerman W.Et., Kniss D.A., et al. Dysferlin is expressed in human placenta but does not associate with caveolin. Biol Reprod 2007, 77:533-542.
49. Izzedine H., Brocheriou I., Eymard B., et al. Loss of podocyte dysferlin expression is associated with minimal change nephropathy. Am J Kidney Dis 2006, 48:143-150.
50. Sharma A., Yu C., Leung C., et al. A new role for the muscle repair protein dysferlin in endothelial cell adhesion and angiogenesis. Arterioscler Thromb Vasc Biol 2010, 30:2196-2204.
51. Vafiadaki E., Reis A., Keers S., et al. Cloning of the mouse dysferlin gene and genomic characterization of the SJL-Dysf mutation. Neuroreport 2001, 12:625-629.
52. Kobayashi K., Izawa T., Kuwamura M., Yamate J. Dysferlin and animal models for dysferlinopathy. J Toxicol Pathol 2012, 25:135-147.
53. Ho M., Post C.M., Donahue L.R., et al. Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency. Hum Mol Genet 2004, 13:1999-2010.
54. Nemoto H., Konno S., Nakazora H., Miura H., Kurihara T. Histological and immunohistological changes of the skeletal muscles in older SJL/J mice. Eur Neurol 2007, 57:19-25.
55. Weller A.H., Magliato S.A., Bell K.P., Rosenberg N.L. Spontaneous myopathy in the SJL/J mouse: pathology and strength loss. Muscle Nerve 1997, 20:72-82.
56. Kobayashi K., Izawa T., Kuwamura M., Yamate J. The distribution and characterization of skeletal muscle lesions in dysferlin-deficient SJL and A/J mice. Exp Toxicol Pathol 2010, 62:509-517.
57. Vainzof M., Ayub-Guerrieri D., Onofre P.C., et al. Animal models for genetic neuromuscular diseases. J Mol Neurosci 2008, 34:241-248.
58. Fanin M., Angelini C. Muscle pathology in dysferlin deficiency. Neuropathol Appl Neurobiol 2002, 28:461-470.
59. Barton E.R., Wang B.J., Brisson B.K., Sweeney H.L. Diaphragm displays early and progressive functional deficits in dysferlin-deficient mice. Muscle Nerve 2010, 42:22-29.
60. Doetschman T. Influence of genetic background on genetically engineered mouse phenotypes. Methods Mol Biol 2009, 530:423-433.
61. Lostal W., Bartoli M., Bourg N., et al. Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer. Hum Mol Genet 2010, 19:1897-1907.
62. von der Hagen M., Laval S.H., Cree L.M., et al. The differential gene expression profiles of proximal and distal muscle groups are altered in pre-pathological dysferlin-deficient mice. Neuromuscul Disord 2005, 15:863-877.
63. Cenacchi G., Fanin M., De Giorgi L.B., Angelini C. Ultrastructural changes in dysferlinopathy support defective membrane repair mechanism. J Clin Pathol 2005, 58:190-195.
64. Selcen D., Stilling G., Engel A.G. The earliest pathologic alterations in dysferlinopathy. Neurology 2001, 56:1472-1481.
65. Deconinck N., Dan B. Pathophysiology of duchenne muscular dystrophy: current hypotheses. Pediatr Neurol 2007, 36:1-7.
66. Dellorusso C., Crawford R.W., Chamberlain J.S., Brooks S.V. Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. J Muscle Res Cell Motil 2001, 22:467-475.
67. Rayavarapu S., Van der Meulen J.H., Gordish-Dressman H., et al. Characterization of dysferlin deficient SJL/J mice to assess preclinical drug efficacy: fasudil exacerbates muscle disease phenotype. PLoS One 2010, 5:e12981.
68. Vieira N.M., Zucconi E., Bueno C.R., et al. Human multipotent mesenchymal stromal cells from distinct sources show different in vivo potential to differentiate into muscle cells when injected in dystrophic mice. Stem Cell Rev 2010, 6:560-566.
69. Faulkner J.A., Ng R., Davis C.S., Li S., Chamberlain J.S. Diaphragm muscle strip preparation for evaluation of gene therapies in mdx mice. Clin Exp Pharmacol Physiol 2008, 35:725-729.
70. Lynch G.S., Hinkle R.T., Faulkner J.A. Force and power output of diaphragm muscle strips from mdx and control mice after clenbuterol treatment. Neuromuscul Disord 2001, 11:192-196.
71. Moens P., Baatsen P.H., Marechal G. Increased susceptibility of EDL muscles from mdx mice to damage induced by contractions with stretch. J Muscle Res Cell Motil 1993, 14:446-451.
72. Petrof B.J., Shrager J.B., Stedman H.H., Kelly A.M., Sweeney H.L. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA 1993, 90:3710-3714.
73. Stupka N., Plant D.R., Schertzer J.D., et al. Activated calcineurin ameliorates contraction-induced injury to skeletal muscles of mdx dystrophic mice. J Physiol 2006, 575:645-656.
74. Ashton-Miller J.A., He Y., Kadhiresan V.A., McCubbrey D.A., Faulkner J.A. An apparatus to measure in vivo biomechanical behavior of dorsi- and plantarflexors of mouse ankle. J Appl Physiol 1992, 72:1205-1211.
75. Roche J.A., Lovering R.M., Bloch R.J. Impaired recovery of dysferlin-null skeletal muscle after contraction-induced injury in vivo. Neuroreport 2008, 19:1579-1584.
76. Roche J.A., Lovering R.M., Roche R., et al. Extensive mononuclear infiltration and myogenesis characterize recovery of dysferlin-null skeletal muscle from contraction-induced injuries. Am J Physiol Cell Physiol 2010, 298:C298-312.
77. Stedman H.H., Sweeney H.L., Shrager J.B., et al. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 1991, 352:536-539.
78. Faulkner J.A. Terminology for contractions of muscles during shortening, while isometric, and during lengthening. J Appl Physiol 2003, 95:455-459.
79. Allen D.G., Zhang B.T., Whitehead N.P. Stretch-induced membrane damage in muscle: comparison of wild-type and mdx mice. Adv Exp Med Biol 2010, 682:297-313.
80. Charge S.B., Rudnicki M.A. Cellular and molecular regulation of muscle regeneration. Physiol Rev 2004, 84:209-238.
81. Li X., Gu W., Masinde G., et al. Genetic control of the rate of wound healing in mice. Heredity 2001, 86:668-674.
82. Grounds M.D., McGeachie J.K. A comparison of muscle precursor replication in crush-injured skeletal muscle of Swiss and BALBc mice. Cell Tissue Res 1989, 255:385-391.
83. Mitchell C.A., McGeachie J.K., Grounds M.D. Cellular differences in the regeneration of murine skeletal muscle: a quantitative histological study in SJL/J and BALB/c mice. Cell Tissue Res 1992, 269:159-166.
84. Roberts P., McGeachie J.K., Grounds M.D. The host environment determines strain-specific differences in the timing of skeletal muscle regeneration: cross-transplantation studies between SJL/J and BALB/c mice. J Anat 1997, 191(Pt 4):585-594.
85. Roche J.A., Ru L.W., Bloch R.J. Distinct effects of contraction-induced injury in vivo on four different murine models of dysferlinopathy. J Biomed Biotechnol 2012, 2012:134031.
86. Nishijo K., Hosoyama T., Bjornson C.R., et al. Biomarker system for studying muscle, stem cells, and cancer in vivo. FASEB J 2009, 23:2681-2690.
87. Buckingham M. Skeletal muscle progenitor cells and the role of Pax genes. C R Biol 2007, 330:530-533.
88. Buckingham M., Montarras D. Skeletal muscle stem cells. Curr Opin Genet Dev 2008, 18:330-336.
89. Chase T.H., Cox G.A., Burzenski L., Foreman O., Shultz L.D. Dysferlin deficiency and the development of cardiomyopathy in a mouse model of limb-girdle muscular dystrophy 2B. Am J Pathol 2009, 175:2299-2308.
90. Han R., Bansal D., Miyake K., et al. Dysferlin-mediated membrane repair protects the heart from stress-induced left ventricular injury. J Clin Invest 2007, 117:1805-1813.
91. Kuru S., Yasuma F., Wakayama T., et al. A patient with limb girdle muscular dystrophy type 2B (LGMD2B) manifesting cardiomyopathy. Rinsho Shinkeigaku 2004, 44:375-378.
92. Wenzel K., Geier C., Qadri F., et al. Dysfunction of dysferlin-deficient hearts. J Mol Med (Berl) 2007, 85:1203-1214.
93. Mahjneh I., Bushby K., Pizzi A., Bashir R., Marconi G. Limb-girdle muscular dystrophy: a follow-up study of 79 patients. Acta Neurol Scand 1996, 94:177-189.
94. Beckmann J.S., Bushby K.M. Advances in the molecular genetics of the limb-girdle type of autosomal recessive progressive muscular dystrophy. Curr Opin Neurol 1996, 9:389-393.
95. Millay D.P., Maillet M., Roche J.A., et al. Genetic manipulation of dysferlin expression in skeletal muscle: novel insights into muscular dystrophy. Am J Pathol 2009, 175:1817-1823.
96. Glover L.E., Newton K., Krishnan G., et al. Dysferlin overexpression in skeletal muscle produces a progressive myopathy. Ann Neurol 2010, 67:384-393.
97. Cox G.A., Cole N.M., Matsumura K., et al. Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity. Nature 1993, 364:725-729.
98. Zhu X., Hadhazy M., Groh M.E., et al. Overexpression of gamma-sarcoglycan induces severe muscular dystrophy. Implications for the regulation of Sarcoglycan assembly. J Biol Chem 2001, 276:21785-21790.
99. Galbiati F., Volonte D., Chu J.B., et al. Transgenic overexpression of caveolin-3 in skeletal muscle fibers induces a Duchenne-like muscular dystrophy phenotype. Proc Natl Acad Sci USA 2000, 97:9689-9694.
100. Matsuda C., Hayashi Y.K., Ogawa M., et al. The sarcolemmal proteins dysferlin and caveolin-3 interact in skeletal muscle. Hum Mol Genet 2001, 10:1761-1766.
101. Hernandez-Deviez D.J., Howes M.T., Laval S.H., et al. Caveolin regulates endocytosis of the muscle repair protein, dysferlin. J Biol Chem 2008, 283:6476-6488.
102. Gazzerro E., Sotgia F., Bruno C., Lisanti M.P., Minetti C. Caveolinopathies: from the biology of caveolin-3 to human diseases. Eur J Hum Genet 2010, 18:137-145.
103. Hernandez-Deviez D.J., Martin S., Laval S.H., et al. Aberrant dysferlin trafficking in cells lacking caveolin or expressing dystrophy mutants of caveolin-3. Hum Mol Genet 2006, 15:129-142.
104. Huang Y., de Morree A., van Remoortere A., et al. Calpain 3 is a modulator of the dysferlin protein complex in skeletal muscle. Hum Mol Genet 2008, 17:1855-1866.
105. Huang Y., Laval S.H., van Remoortere A., et al. AHNAK, a novel component of the dysferlin protein complex, redistributes to the cytoplasm with dysferlin during skeletal muscle regeneration. FASEB J 2007, 21:732-742.
106. Matsuda C., Miyake K., Kameyama K., et al. The C2A domain in dysferlin is important for association with MG53 (TRIM72). PLoS Curr 2012, 4. e5035add5038caff5034.
107. Cacciottolo M., Belcastro V., Laval S., et al. Reverse engineering gene network identifies new dysferlin-interacting proteins. J Biol Chem 2011, 286:5404-5413.
108. van Haagen H.H., T Hoen P.A., de Morree A., et al. In silico discovery and experimental validation of new protein-protein interactions. Proteomics 2011, 11:843-853.
109. Wagner K.R. Approaching a new age in Duchenne muscular dystrophy treatment. Neurotherapeutics 2008, 5:583-591.
110. Bushby K. Understanding the heterogeneity of the limb-girdle muscular dystrophies. Biochem Soc Trans 1996, 24:489-496.
111. Rawat R., Cohen T.V., Ampong B., et al. Inflammasome up-regulation and activation in dysferlin-deficient skeletal muscle. Am J Pathol 2010, 176:2891-2900.
112. Feuk-Lagerstedt E., Movitz C., Pellme S., Dahlgren C., Karlsson A. Lipid raft proteome of the human neutrophil azurophil granule. Proteomics 2007, 7:194-205.
113. Ho M., Gallardo E., McKenna-Yasek D., et al. A novel, blood-based diagnostic assay for limb girdle muscular dystrophy 2B and Miyoshi myopathy. Ann Neurol 2002, 51:129-133.
114. Jethwaney D., Islam M.R., Leidal K.G., et al. Proteomic analysis of plasma membrane and secretory vesicles from human neutrophils. Proteome Sci 2007, 5:12.
115. De Luna N., Freixas A., Gallano P., et al. Dysferlin expression in monocytes: a source of mRNA for mutation analysis. Neuromuscul Disord 2007, 17:69-76.
116. Gros P., Milder F.J., Janssen B.J. Complement driven by conformational changes. Nat Rev Immunol 2008, 8:48-58.
117. Wessels M.R., Butko P., Ma M., et al. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc Natl Acad Sci USA 1995, 92:11490-11494.
118. Bosma G.C., Custer R.P., Bosma M.J. A severe combined immunodeficiency mutation in the mouse. Nature 1983, 301:527-530.
119. Diaz-Manera J., Touvier T., Dellavalle A., et al. Partial dysferlin reconstitution by adult murine mesoangioblasts is sufficient for full functional recovery in a murine model of dysferlinopathy. Cell Death Dis 2010, 1:e61.
120. Kostek C.A., Dominov J.A., Miller J.B. Up-regulation of MHC class I expression accompanies but is not required for spontaneous myopathy in dysferlin-deficient SJL/J mice. Am J Pathol 2002, 160:833-839.
121. Nadeau J.H., Singer J.B., Matin A., Lander E.S. Analysing complex genetic traits with chromosome substitution strains. Nat Genet 2000, 24:221-225.
122. Thomsen M., Galvani S., Canivet C., Kamar N., Bohler T. Reconstitution of immunodeficient SCID/beige mice with human cells: applications in preclinical studies. Toxicology 2008, 246:18-23.
123. Smith M.K., Wakimoto B.T. Complex regulation and multiple developmental functions of misfire, the Drosophila melanogaster ferlin gene. BMC Dev Biol 2007, 7:21.
124. Kawahara G., Serafini P.R., Myers J.A., Alexander M.S., Kunkel L.M. Characterization of zebrafish dysferlin by morpholino knockdown. Biochem Biophys Res Commun 2011, 413:358-363.
125. Krajacic P., Hermanowski J., Lozynska O., Khurana T.S., Lamitina T. Caenorhabditis elegans dysferlin homolog fer-1 is expressed in muscle, and fer-1 mutations initiate altered gene expression of muscle enriched genes. Physiol Genomics 2009, 40:8-14.
126. Potgieter M., Pretorius E., Van der Merwe C.F., et al. Histological assessment of SJL/J mice treated with the antioxidants coenzyme Q10 and resveratrol. Micron 2011, 42:275-282.
127. Aartsma-Rus A., Singh K.H., Fokkema I.F., et al. Therapeutic exon skipping for dysferlinopathies?. Eur J Hum Genet 2010, 18:889-894.
128. Barthelemy F., Wein N., Krahn M., Levy N., Bartoli M. Translational research and therapeutic perspectives in dysferlinopathies. Mol Med 2011, 10:10-15.
129. Wang B., Yang Z., Brisson B.K., et al. Membrane blebbing as an assessment of functional rescue of dysferlin-deficient human myotubes via nonsense suppression. J Appl Physiol 2010, 109:901-905.
130. Welch E.M., Barton E.R., Zhuo J., et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007, 447:87-91.
131. Grounds M.D., Radley H.G., Lynch G.S., Nagaraju K., De Luca A. Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol Dis 2008, 31:1-19.
132. Jang W., Weber J.S., Bashir R., Bushby K., Meisler M.H. Aup1, a novel gene on mouse chromosome 6 and human chromosome 2p13. Genomics 1996, 36:366-368.
133. Sher R.B., Cox G.A., Mills K.D., Sundberg J.P. Rhabdomyosarcomas in aging. A/J mice. PLoS One 2011, 6:e23498.